CLENSTA expands partnership with CIPLA to improve access to personal hygiene

Our Bureau

Clensta International, an IIT Delhi partnered healthcare start-up revolutionizing the personal hygiene space, recently announced extension of their marketing and distribution partnership with Cipla, one of the leading global pharmaceutical company in India for its waterless technology products. This deal will redefine the hygiene and cleanliness for patients in hospital setups, primarily focusing on ICUs where patients don’t have easy access to bathing and likewise, Government & defense forces who are located in remote locations and cannot take bath easily.

In the statement, the company added, “Clensta strongly believes in innovation backed by scientific studies and sustainability and our waterless products have helped patients and soldiers around the world and saved 400 million liters of water till now. Moving further, Cipla will run an intensive marketing drive to educate the right buyers as planned. They target to make this one of their successful portfolios where they’ll be redefining the cleaning process through their various teams for promoting the product at various levels in Indian territory aiming towards expanding maximum reach to hospitals, pharmacies, defense and various institutions. This is a step taken on PAN-India level in continuation of efforts made by Clensta so far.”

Puneet Gupta, Founder, and CEO, Clensta International said “Personal hygiene is a necessity and everyone must have it, we feel obliged that we are contributing our bit through our waterless products. This strategic partnership with Cipla is an important step in our journey to redefine bathing without exhausting water. We see significant synergies between the two companies especially on brand relationships and consumer experience.”

Author

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

A combination between AstraZeneca and the first component of Sputnik V vaccine (Sputnik Light) demonstrates high immunogenicity profile in the clinical study in Azerbaijan

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), AstraZeneca and R-Pharm announce preliminary results on immunogenicity of combined use of the AstraZeneca vaccine (developed jointly with the University of Oxford) and the first component of the Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) […]

Subscribe Now